Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge.
Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the production capacity, alternative systems based on antibody production in transgenic organisms are being actively explored. In this paper, we focus on transgenic plants as a promising system for the scale-up and processing of plant-made pharmaceuticals. In particular, we point out the advantages and limitations induced by glycosylation of plant-made antibodies for human therapy.
Gomord
Véronique
V
CNRS UMR 6037, IFRMP 23, GDR 2590 - Université de Rouen, 76821 Mont Saint Aignan Cedex, France. vgomord@crihan.fr
Sourrouille
Christophe
C
Fitchette
Anne-Catherine
AC
Bardor
Muriel
M
Pagny
Sophie
S
Lerouge
Patrice
P
Faye
Loïc
L